Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 8
Submit an article Journal homepage
58
Views
14
CrossRef citations to date
0
Altmetric
Miscellaneous

Experimental and emerging therapies for sepsis and septic shock

Ramon L Añel
&
Anand Kumar
Pages 1471-1485 | Published online: 24 Feb 2005

Bibliography

  • BONE RC, BALK RA, CERRA FB et at Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest (1992) 101:1644–1655.
  • ANEL R, DELLINGER RP: Sepsis and bacteremia. In: Corith Current Therapy Rake! RE, Bope ET (Eds.), WB Saunders Co. (2001):56–62.
  • WEIL MH, MACLEAN CD, FISSEHER MB, SPINK WW: Studies of the circulatory changes in the dog produced by endotoxin from Gram-negative microorganisms. J. Clin. Invest. (1956) 35:1191–1198.
  • SWINGLE WW, PFIFFNER JJ: An aqueous extract of the suprarenal cortex which maintains the life of adrenalectomized cats. Science (1930) 71:321–322.
  • HARTMAN FA, SCOTT WJM: Protection of adrenalectomized animals against bacterial intoxication by an extract of the adrenal cortex. J. Exp. Med. (1932) 55:63–69.
  • ANNANE D, SEBILLE V, TROCHE G et al.: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA (2000) 283:1038–1045.
  • ZALOGA GP: Sepsis-induced adrenal deficiency syndrome. Grit. Care Med. (2001) 29:688–690.
  • ROBSON HG, CLUFF LE: Experimental pneumococcal and staphylococcal sepsis: the effects of hydrocortisone and phenoxybenzamine upon mortality rate. J. Gun. Invest. (1966) 45:1432.
  • FABIAN TC, PATTERSON R: Steroid therapy in septic shock. Survival study in a laboratory model. Am. Surgeon (1982) 48:614–617.
  • HINSHAW LB, ARCHER LT, BELLER TODD BK etal.: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ. Shock (1981) 8:291–300.
  • HINSHAW LB, BELLER TODD BK, ARCHER LT et at Recovery from lethal Escherichia mlishock in dogs. Surg. CyrrecoL Obstet. (1979) 149:545–553.
  • HINSHAW LB, ARCHER LT, BELLER TODD BK etal.: Survival in primates in lethal septic shock following delayed treatment with steroid. Circ. Shock (1981) 8:291–300.
  • SCHUMER W: Steroids in the treatment of clinical septic shock. Ann. Surg. (1976) 184:333–341.
  • SPRUNG CL, CARALIS PV, MARCIAL EH et al.: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl. J. Med. (1984) 311:1137–1143.
  • BONE RC, FISCHER CJ JR, CLEMMERTP et al.: A controlled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N ErigL Med. (1987) 317:653–658.
  • THE VETERANS ADMINISTRATION SYSTEMIC SEPSIS COOPERATIVE STUDY GROUP: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis, N ErigL J. Med. (1987) 317:659–665.
  • LUCE JM, MONTGOMERY AB, MARKS JD etal.: Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am. Rev Respir Dis. (1998) 138:62–68.
  • LEFERING R, NEUGEBAUER EAM: Steroid controversy in sepsis and septic shock: A meta-analysis. Grit. Care Med. (1995) 23:1294–1303.
  • CRONIN L, COOK DJ, CARLET J etal.:Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Grit. Care Med. (1995) 23:1430–1439.
  • CARLET J: Immunological therapy in sepsis: Currently available. Intensive Care Med. (2001) 27:S93–S103.
  • LEBEL MH, FEIJI BJ, SYROGAINNOPOLOUS GA et at Dexamethasone therapy for bacterial meningitis: Results of two, double-blind, placebo-controlled trials. N ErigL J. Med. (1988) 319:964–971.
  • HOFFMAN SL, PUNJABI NH, KUMALA S et al.: Reduction in mortality in chloramphenicol treated severe typhoid fever by high-dose dexamethasone. N ErigL J. Med. (1984) 310:82–88.
  • GAGNON S, BOOTA AM, FISCHL MA etal.: Corticosteroids as adjunctive therapy for Pneumocystic carinii pneumonia in the acquired immunodeficiency syndrome. N ErigL J. Med. (1990) 323:1440–1450.
  • MONTANER JS, LAWSON LM, LEVITT M et al.: Corticosteroids prevent early deterioration in patients with moderate severe Pneumocytis carinii pneumonia and the acquired immunodeficiency syndrome. Ann. Intern. Med. (1990) 113:14–20.
  • MEDURI GU, HEADLEY ASH, GOLDEN E et al: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA (1998) 280:159–165.
  • BOLLAERT PE, CHARPENTIER C, LEVY S et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Grit. Care Med. (1998) 26:645–650.
  • CHAWLA K, KUPFER Y, GOLDMAN I, TESSLER S: Hydrocortisone reverses refractory septic shock. Grit. Care Med. (1999) 27(Suppl):A33
  • BRIEGEL J, FOREST H, HALLER M et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock; A prospective, randomized, double-blind, single-center study. Grit. Care Med. (1999) 27:723–732.
  • BRIEGEL J, JOCHUM M, GIPPNER-STEPPERT C, THIEL M: Immunomodulation in septic shock: Hydrocortisone differentially regulates cytokine reponses. j Am. Soc. Nephrol. (2001) 12\(Suppl. 17):570–574.
  • ANNANE D: Effects of the combination of hydrocortisone-fludrocortisone on mortality in septic shock. Grit. Care Med. (2000) 28:A46 (Abstract).
  • MARIK P, ZALOGA G: Prognostic value of cortisol response in septic shock. (letter; comment). JAMA (2000) 284:308–309.
  • MARIK PE, KIMINYO K, OLEXO S et al.: Occult adrenal insufficiency in critically ill patients. An underdiagnosed entity. (abstract) Grit. Care Med. (1999) 27:A141.
  • SONI A, PEPPER GM, WYRWINSKI PM et al.: Adrenal insufficiency occurring during septic shock: Incidence, outcome, and relationship to peripheral cytokine levels. Am J. Med. (1995) 98:266–271.
  • KERI G, PARAMESWARAN V, RAMACHANDIAN J et at Mechanisms of adrenocortical cell function. Life Sri. (1981) 28:1917–1923.
  • ZHU Q, SOLOMON S: Isolation and mode of action of rabbit corticostatin (antiadrenocorticotropin) peptides. Endocrinology (1991) 128:623–629.
  • KOO DJ, JACKMAN D, CHAUDRY IH et al.: Adrenal insufficiency during the late stage of polymicrobial sepsis. Grit. Care Med. (2001) 29:618–622.
  • FINDLING JW, WATERS VO, RAFF H: The dissociation of renin and aldosterone 1482 during critical illness. J. CM]. Endocrinol. Metabol (1987) 64:592–595.
  • CHRISTEFF N, CARLI A, BENASSAYAG C etal.: Relationship between changes in serum estrone levels and outcome in human males with septic shock. Circ. Shock (1992) 36:249–255.
  • WHEELER AE BERNANRD GR: Treating patients with severe sepsis. N Engl. J. Med. (1999) 340:207–214.
  • DINARELLO CA, GELFAND GA, WOLFF SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA (1993) 269(14):1829–1835.
  • ROSENBERG RD, AIRD WC: Vascular-bed-specific hemostasis and hypercoagulable states. N Eng1J. Med. (1999) 340:1555–1564.
  • ESMON NL, ESMON CT: Protein C and the endothelium. Semir]. Thromb. Hemost. (1988) 14:210–215.
  • HERBERT PC, DRUMMOND AJ, SINGER J et al: A simple multiple organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest (1993) 104:230–235.
  • GANDO S, NANZAKI S, SASAKI S et al.:Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Grit. Care Med. (1998) 26:2005–2009.
  • MESTERS R, HELTERBRAND J, UTTERBACK BG et al.: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit. Care Med. (2000) 28:2209–2216.
  • SCHMIDT-SUPPRIAN M, MURPHY C, WHILE B et al.: Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur. Cytokine Network (2000) 11:407–413.
  • TAYLOR FB JR: Studies on the inflammatroy-coagulant axis in the baboon response to E. Colt. regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Frog. Clin. Biol. Res. (1994) 388:175–194.
  • LORENTE JA, GARCIA-FRADE LJ, LANDIN L et al: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest (1993) 103:1536–1542.
  • MESTERS RM, MANNUCCI PM, COPPOLA E et al: Factor VIIA and antithrombin III activity during sever sepsis and septic shock in neutropenic patients. Blood (1996) 88:881–886.
  • ABRAHAM E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Grit. Care Med. (2000) 28(9 Suppl):531–533.
  • BLAUHUT B, NECEK S, VINAZZER H et al.: Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb. Res. (1982) 27:271–278.
  • FOURRIER F, CHOPIN C, HUART JJ et al.: Double-blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest (1993) 104:882–888.
  • BALK RA, BEDROSSIAN C, MCCORMICK L et al: Prospective, double-blind, placebo-controlled trial of ATIII substitution in sepsis (Abstract). Intensive Care Med. (1995) 21\(Suppl. 1):517.
  • BAUDO F, CAIMI TM, DE CATALDO E etal.: Antithrombin III replacement therapy in patients with sepsis and/or surgical complications: A controlled, double-blind, randomized, multicenter study. Intensive Care Med. (1998) 24:336–342.
  • EISELE B, LAMY M, THUS LG et al: Antithrombin III in patients with severe sepsis: A randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized placebo-controlled multicenter trials with antithrombin III in severe sepsis. Intensive Care Med. (1998) 24:663–672.
  • FOURRIER F, JOURDAIN M, TOURNOYS A: Clinical trial results with anithrombin III in sepsis. Grit. Care Med. (2000) 28(9 Suppl.):538–543.
  • SMITH D: Meeting Report: 13th Annual Congress of the European Society of Intensive Care Medicine, Rome, Italy, 1-4 October 2000 Grit. Care (2000) 4:347–351.
  • OPAL SM, PALARDY JE, PAREJO NA, CREASEY AA: The activity of tissue pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial sepsis. Grit. Care Med. (2001) 29:13–17.
  • DE JONGE E, DEKKERS PEP, CREASEYAA et al.: Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood (2000) 95:1124–1129.
  • TAYLOR FB JR, CHANG A, EAMON CT et al.: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in baboons. J. Chi]. Invest (1987) 79:918–925.
  • BERNARD GR, VINCENT JL, LATERRE PF etal.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl. J. Med. (2001) 344:699–709.
  • MAY RD, HAWKSWOOD E, POWLING MJ: Superior efficacy of low molecular weight thrombin inhibitors in a novel in vitro model of clot bound thrombin. Blood (1994) 5:943–949.
  • ERIKSSON M, LARSSON A, SALDEEN T, MATTSSON C: Melagatran, a low molecular weight thrombin inihibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb. Haemost. (1998) 80:1022–1026.
  • ERIKSSON M, SALDEEN T, MATTSSON C, LARSSON A: Effects of melagatran, an inihibitor of thrombin, on fibrin deposits, haemodynamics and platelet count in endotoxaemic pigs. Acta Anesthesia. Land. (2000) 44:24–31.
  • VOLANAKIS JE: Overview of the complement system. In: The Human Complement System in Health and Disease, Volanakis JE, Frank MM, (Eds.), Marcel Dekker, Inc., New York (1998):9.
  • ASGHAR SS, PASCH MC: Therapeutic inhibition of the complement system. Front Biosci (2000) 5:E63–E81.
  • HACK, OLGIVIE, EISELE et al: Cl-inhibitor substitution therapy in septic shock and in vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. (1993) 19:S19–S28.
  • NORNBERGER, MICHELMANN, PETRIK etal.: Acivity of Cl-esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann. Hematology (1993) 67:17–21.
  • ZEERLEDER S, CALIEZI CH, REDONDO M et al.: Activation of the plasmatic cascade in sepsis: Role of Cl-inhibitor. Schweiz Med. Wochenschr (1999) 129:1410–1417.
  • HUBER-LANG MS, SARMA JV, MCGUIRE SR etal.: Protective effects of anti-05a peptide antibodies in experimental sepsis. FASEB J. (2001) 15:568–570.
  • LEAVER HA, QU JM, SMITH G et al: Endotoxin releases platelet-activating factor from human monocytes in vitro. Immunopharmacology (1990) 20:105–113.
  • MYERS AK, ROBEY JW, PRICE RIVI: Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br j Pharmacol (1990) 99:499–502.
  • SERHAN CN, HAEGGSTROM JZ, LESLIE CC: Lipid mediator networks in cell signaling: Update and impact of cytokines. FASEB J. (1996) 10:1147–1158.
  • MAEIR RV, HAHNEL GB, FLETCHER JR: Platelet-activating factor augments tumor necrosis factor and procoagulant activity. J. Surg. Res. (1992) 52:258–264.
  • SZABO C, WU CC, MITCHELL JA et al: Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ. Res. (1993) 73:991–999.
  • HERBERTSON MJ, WERNER HA, WALLEY KR: Platelet-activating factor antagonism improves ventricular contractility in endotoxemia. Grit. Care Med. (1997) 259:221–226.
  • SIEBECK M, WEIPERT J, KESER C et al.: A triazolodiazepine platelet-activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxic shock in swine. J. Trauma (1991) 31:942–950.
  • ONO S, MOCHIZUKI H, TAMAKUMA S: A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am. J. Surg. (1996) 171:409–415.
  • GRAHAM RIVI, STEPHENS CJ, SILVESTER W et al: Plasma degredation of platelet-activating factor in severely ill patients with clinical sepsis. Grit. Care Med. (1994) 22:204–212.
  • FLETCHER JR, DISIMONE AG, EARNEST MA: Platelet-activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann. Surg. (1990) 211:312–316.
  • KRUSE-ELLIOT KT, ALBERT DH, SUMMERS JB et al: Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock (1996) 5:265–273.
  • NEWALL CA, ANDERSON LA, PHILLIPSON JD: Ginkgo Biloba monograph. In: Herbal Medicines: A Guide for Health-Care Professionals, Pharmaceutical Press, London (1996):138.
  • KOLTAI M, OSFORD D, GUINOT P et al.: Platelet activating factor: A review of its effects antagonists and possible future applications (Parts I and II). Drugs (1991) 42:9-29, 174–204.
  • DHAINAUT JFA, TENAILLON A, LE TULZO Y etal.: Platelet-activating factor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Grit. Care Med. (1994) 22:1720–1728.
  • DHAINAUT JFA, TENAILLON A, HEMMER M et al.: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis. A Phase III, randomized, double-blind, placebo-controlled, multicenter trial. Grit. Care Med. (1998) 26:1936–1971.
  • SUPUTTAMONGKOL Y, INTARANONGPAI S, SMITH MD et al: A double-blind placebo-controlled study of an infuxion of lexipafant (platelet-activating factor antagonist) in patients with severe sepsis. Antimicrob. Agents Chemother. (2000) 44:693–696.
  • VINCENT JL, SPAPEN H, BAKKER J et al.: Phase II multicenter clinical study of the platelet-activating factor resceptor antagonist BB-882 in the treatment of sepsis. Grit. Care Med. (2000) 28:638–642.
  • TAGGART DP: Effects of a platelet-activating factor antagonist on lung injury and ventilation after cardiac operation.
  • JOHNSON CD, KINGSNORTH AN, IMRIE CW et al.: Double blind, randomized, placebo-controlled study of a platelet-activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Cut (2001) 48:62–69.
  • TJOELKER LW, STAFFORINI DM: Platelet-activating factor acetylhydrolases in health and disease. Biochimica et Biophysica Acta (2000) 1488:102–123.
  • HENDERSON WR, LU JY, POOLE KM etal.: Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. ..J. Immunol (2000) 164:3360–3367.
  • HENIG NR, AITKEN ML, LIU MC et al.:Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am. Resp. Grit. Care Med. (2000) 162:523–527.
  • SHERMAN S, LEHMAN GA, GEENEN Jet al.: Evaluation of recombinant human platelet-activating factor acetylhydrolase (rPAF-AH) for reducing the incidence and severity of post-ERCP acute pancreatitis. Gastrointestinal Endoscopy (2000) 51:3346–3346.
  • KUMAR A, KRIEGER A, SYMEONEIDES S, PARILLO J: Myocardial dysfunction in septic shock, part II. Role of cytokines and nitric oxide. J. Cardiovasc. Thoracic Ariesth (In Press).
  • LAMAS S, MICHEL T: Molecular and biological features of nitric oxide synthase isofroms. In: Nitric Oxide and the Lung. Zapol W, Bloch KD, eds. Marcel Dekker, New York (1996):59
  • LAMAS S, MICHEL T: Endothelium-derived nitric oxide and control of vascular tone. In: Principles of Molecular Medicine. Jameson JL (Ed.), Humana Press, New Jersy, USA (1998):141.
  • WHITTLE B: Nitric oxide in physiology and pathology. Histochem. J. (1995) 27:727–737.
  • DUSTING G: Nitric oxide in cardiovascular disorders. J. Vase. Res. (1995) 32:143–161.
  • SZABO C: The pathophysiological role ofperoxynitrite in shock, inflammation and ischemia-reperfusion injury. Shock (1996) 6:79–88.
  • GROVER R, BAKKER J, MCLUCKIE A et al.: The nitric oxide synthase inhibitor, 546C88, promotes the resolution of shock in patients with severe sepsis. Grit. Care Med. (1998) 26\(Suppl. 1):29A (Abstract).
  • BAKKER J, WEG, J, ZACCARDELLI D et al.: Multi-center, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor, 546C88, in patients with septic shock: Effects on cardiovascular function. (abstract) Grit. Care Med. (1998) 26(Suppl. I):63A.
  • GROVER R, ZACCARDELLI D, COLICE G et al: An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Grit. Care Med. (1999) 27:913–922.
  • GROVER R, LOPEZ A, LORENTE J et al.: Multi-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect in survival in patients with septic shock. Grit. Care Med. (1999) 27:33A.
  • KUMAR A, OSMAN J: Septic myocardial depression: No 'no' to NO? (editorial) Grit. Care Med. (2001) 29:202–203.
  • THIEMERMANN C, RUETTEN H, WU C et al.: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J. Pharmacol (1995) 116:2845–2851.
  • FATEHI-HASSANABAD Z, BURNS H, AUGHEY E et al.: Effects of L-canavanine, an inhibitor of inducible nitric oxide synthase on endotoxin mediated shock in rats. Ain. J. Physiol (1996) 6:194–200.
  • BUNE A, BRAND M, HEALES S et al: Inihbition of tetrahydrobiopterin synthesis reduces in vitro nitric oxide production in experimental endotoxic shock. Biochein. Biophys. Res. Comm 220:13–19.
  • FRICKER SP: Nitric oxide scavengers as a therapeutic approach to nitric oxide mediated disease. Expert Opin. Investig. Drugs (1999) 8:1209–1222.
  • SIELENKAMPER AW, CHIN-YEE IH, MARTIN CM et al.: Diaspirin crosslinked hemoglobin improves systemic oxygen uptake in oxygen supply-dependent septic rats. Am J. Respir Grit. Care Med. (1997) 156:1066–1072.
  • WINSLOW RM, GONZALES A, GONZALES ML et al: Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. I Appl. Physiol (1998) 85:993–1003.
  • CRETEUR J, VINCENT JL: Hemoglobin solutions: An 'all-in-one' therapeutic strategy in sepsis? (editorial) Grit. Care Med. (2000) 28:894–896.
  • SLOAN EP, KOENISBERG M, GENS D et al: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhage. JAMA (1999) 282:1857–1864.
  • BONE HG, FISCHER SR, SCHENARTS PJ et al.: Continuous infusion of pyridoxilated hemoglobin polyoxyethylene conjugate in hyperdynamic septic sheep. Shock (1998) 10:69–76.
  • MOLINA L, STUDENBERG S, WOLBERG G etal.: Efficacy of treatment with iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherechia coil. j Gift]. Invest. (1996) 98:192–198.
  • GREENBERG S, XIE J, ZATARAIN JM et al.: Hydroxycobalamin prevents and reverses endotoxin-induced hypotension and mortality in rodents: Role of nitric oxide. J. Pharmacol Exp. Ther. (1995) 273:257–265.
  • FRICKER SP: Ruthenium, nitric oxide and disease. Plainum Metals Rev (1995) 39:150–159.
  • DENNER L: Caspases in apoptotic death. Expert Opin. Investig. Drugs (1999) 8:37–50.
  • CASTELINO DJ, MCNAIR P, KAY TW: Lymphocytopenia in a hospital population - what does it signify? Aust. NZ J. Med. (1997) 27:170–174.
  • HOTCHKISS RS, SWANSON PE, FREEMAN BD et al.: Apoptotic cell death in patients with sepsis, shock and multiple organ dysfunction. Grit. Care Med. (1999) 27:1230–1251.
  • TINSLEY, KW, CHENG SL, BUCHMAN TG et al: Caspase-2,-3,-6, and -9 but not caspase-1, are activated in sepsis-induced thymocyte apoptosis. Shock (2000) 13:1–7.
  • OBERHOLZER C, OBERHOLZER A, CLARE-SALZLER M, MOLDAWER L: Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. (2001) 15:879–892.
  • AYALA A, CHUNG CS, SONG GY, CHAUDRY IH: I1-10 mediation of activation-induced th(l)cell apoptosis and lymphoid dysfunction in polymicrobial sepsis. Cytokine (2001) 14:37–48.
  • BRAUN JS, NOVAK R, HERZOG KH et al.: Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med. (1999) 5:298–302.
  • HOTCHKISS RS, TINSLEY KW, SWANSON PE et al.: prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad Sci (1999) 96: 14541–14546.

Websites

  • www.anesthesiologyonline.com MCGRATH B: Perioperative management of sepsis and septic shock. Anesthesiology Online (2000)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.